Compare · CELC vs CI
CELC vs CI
Side-by-side comparison of Celcuity Inc. (CELC) and The Cigna Group (CI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELC and CI operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $76.61B, about 18.0x CELC ($4.26B).
- Over the past year, CELC is up 618.5% and CI is down 5.8% - CELC leads by 624.3 points.
- CELC has been more active in the news (16 items in the past 4 weeks vs 4 for CI).
- CI has more recent analyst coverage (25 ratings vs 14 for CELC).
- Company
- Celcuity Inc.
- The Cigna Group
- Price
- $92.80+6.23%
- $293.18+1.27%
- Market cap
- $4.26B
- $76.61B
- 1M return
- -29.19%
- +1.79%
- 1Y return
- +618.54%
- -5.79%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 16
- 4
- Recent ratings
- 14
- 25
Celcuity Inc.
Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest CELC
- Celcuity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Celcuity Inc.
- SEC Form 305B2 filed by Celcuity Inc.
- Chief Science Officer Laing Lance G. exercised 1,000 shares at a strike of $9.89, increasing direct ownership by 0.08% to 1,251,000 units (SEC Form 4)
- SEC Form FWP filed by Celcuity Inc.
- Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
- Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
- SEC Form 424B5 filed by Celcuity Inc.
- Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer
- Celcuity Inc. filed SEC Form 8-K: Regulation FD Disclosure
Latest CI
- EVP, Global CIO Koka Durga Prasad covered exercise/tax liability with 729 shares, decreasing direct ownership by 10% to 6,552 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Kurian George
- The Cigna Group downgraded by Barclays with a new price target
- The Cigna Group downgraded by Deutsche Bank with a new price target
- Chairman & CEO Cordani David exercised 212,543 shares at a strike of $170.34 and sold $59,114,186 worth of shares (201,878 units at $292.82) as part of a pre-agreed trading plan, increasing direct ownership by 23% to 57,766 units (SEC Form 4)
- The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure
- The Cigna Group Announces Appearance at the BofA Securities 2026 Health Care Conference
- Kayne Anderson Energy Infrastructure Fund Announces Appointment of Michael J. Hennigan as New Independent Director
- SEC Form 144 filed by The Cigna Group
- SEC Form 10-Q filed by The Cigna Group